🧠 Food for thought

Implications, context, and why it matters.

The deal’s real value hinges on undisclosed target details and milestone structure

• Insilico touts a US$888 million Servier deal. Gaps remain on target counts and exclusivity terms. Investors also lack required stages, royalty rates, or any co-development or co-commercialization rights. Only up to US$32 million is near term R&D cash. The balance, up to US$856 million, ties to milestones and other payments 1. Milestones usually link to R&D, regulatory, or sales goals, so cash may take years or never land.
• Between 2021 and 2024, Insilico nominated 20 preclinical candidates, testing about 60 to 200 molecules per program 1. That pace cuts discovery timelines to 12 to 18 months 2. Oncology trials often run for years, which delays milestone revenue.

Biotech investors can capitalize on Hong Kong Exchanges and Clearing (HKEX)’s 2026 pipeline of AI-drug and oncology listings

• Insilico ran the largest Hong Kong biotech IPO of 2025, raising HKD 2.277 billion, and the public tranche (the retail investor portion) was oversubscribed 1,427 times 3.
• Chapters 18A plus 18C of HKEX listing rules opened the door to pre-revenue biotech and specialist technology issuers. Since then, 88 such companies have listed 4. 2026 forecasts call for at least 160 new Hong Kong listings and at least HKD 300 billion raised, with seven mega-IPOs above HKD 10 billion 5. Investors can map 300+ pending HKEX applications to find pre-IPO entries or anchor allocations, with a focus on US-listed China concept stocks (China-based companies listed on US exchanges) and healthcare firms 5.